Breaking News

Curia Launches Comprehensive mRNA Offering

mRNA services combine experience and capabilities from discovery through fill-finish manufacturing.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Curia, formerly AMRI, a contract research, development and manufacturing organization, unveiled its messenger RNA (mRNA) ofering, which includes discovery, process development and mRNA drug substance production, through large-scale lipid manufacturing, lipid nanoparticle (LNP) formulation and development for full-scale sterile fill-finish services.   The mRNA service is designed to streamline the development and delivery of mRNA-based products, which span various therapeutic areas including ca...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters